Over the past couple of weeks, a lot has happened within the insulin drug class.  It started on March 1, when Eli Lilly announced price reductions of 70% on its commonly prescribed insulins and an expansion of its Insulin Value Program that caps out-of-pocket costs at $35 per month.  Then, last week, Novo Nordisk and […]